Endeavor

Drug Offers New Option for Patients With Rare Blood Disorders in ‘No Man’s Land’

Fedratinib is approved to treat myelofibrosis and could be effective in myelodysplastic/myeloproliferative neoplasms

Get to Know Moffitt Physician in Chief Dr. Karen Lu

Karen Lu, MD, is a nationally recognized physician-scientist who focuses her clinical and research interests on the surgical and medical treatment of women with ovarian and endometrial cancers

Newly Approved CAR T-Cell Therapy Gives Acute Lymphoblastic Leukemia a New Personalized Option

Novel design and tumor-guided dosing may reduce side effects while maintaining encouraging efficacy

New Cancer Vaccine May Boost Immunotherapy in Treating Lung Cancer

Phase 2 trial results suggest IO102-IO103 combined with pembrolizumab may enhance response rates in advanced lung cancer

A Novel Class of Therapeutic Biologics Shows Promise for HPV-Related Head and Neck Cancer

Combining two treatments may improve outcomes for patients with HPV 16–positive disease

Moffitt Experts’ Study Aims to Improve TIL Therapy Process

Tumor-infiltrating lymphocyte therapy is FDA approved to treat melanoma.

New Combination Therapy Brings Hope to Bladder Cancer Patients

Oncolytic immunotherapy and immune checkpoint inhibitor found to be safe and effective in treating muscle-invasive bladder cancer

New Immunotherapy Strategy Shows Promise in Lung Cancer Treatment

Moffitt researchers advance a novel approach to boost the immune system’s ability to target lung cancer cells

New Immunotherapy Combination Shows Promise in Advanced Lung Cancer

Adding pembrolizumab to TIL therapy shrunk tumors in almost half of trial patients